Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January

Iterum Therapeutics plc (NASDAQ:ITRM) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 1,790,000 shares, a drop of 5.3% from the January 15th total of 1,890,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 1.8 days. Approximately 5.3% of the company’s stock are short sold.

Hedge Funds Weigh In On Iterum Therapeutics

Hedge funds have recently bought and sold shares of the company. Lee Financial Co acquired a new position in Iterum Therapeutics in the fourth quarter worth about $28,000. Sanctuary Advisors LLC acquired a new position in Iterum Therapeutics in the fourth quarter worth about $35,000. Citadel Advisors LLC acquired a new position in Iterum Therapeutics in the fourth quarter worth about $38,000. Two Sigma Investments LP acquired a new position in Iterum Therapeutics in the fourth quarter worth about $45,000. Finally, XTX Topco Ltd acquired a new position in Iterum Therapeutics in the third quarter worth about $36,000. 9.21% of the stock is currently owned by institutional investors and hedge funds.

Iterum Therapeutics Stock Performance

NASDAQ:ITRM opened at $1.49 on Wednesday. The company has a market capitalization of $41.00 million, a price-to-earnings ratio of -0.75 and a beta of 2.28. Iterum Therapeutics has a one year low of $0.81 and a one year high of $3.02. The stock has a 50-day simple moving average of $1.66 and a 200 day simple moving average of $1.45.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.